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Angiotensin converting enzyme (ACE) catalyses the 
conversion of angiotensin I (Ang I) to angiotensin II 
(Ang II). The ACE activity directly related to hyperten-
sion as Ang II is the blood pressure regulating hormone. 
Therefore, ACE inhibitors are a major class of anti-
hypertensive drugs. Captopril, chemical name, was 
the first orally active ACE inhibitory antihypertensive 
drug, discovered in 1977. Since then, a number of such 
drugs have been synthesized. Enzyme-inhibitor bound 
crystal structural studies reveal a great deal of under-
standing about the interactions of the inhibitors at the 
active site of ACE. This can be helpful in the rational 
design of ACE inhibitors. With the advancement  
of the combination therapy, it is known that ACE  
inhibitors having antioxidant activity can be beneficial 
for the treatment of hypertension. This study describes 
the development of ACE inhibitors in the treatment of 
hypertension. Importance of ACE inhibitors having 
antioxidant activity is also described. 
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Introduction 
BLOOD pressure (BP) is a quantitative term and is highly 
variable from person to person. The normal BP for an in-
dividual should be 120/80 mm Hg. According to a WHO, 
if BP exceeds 140/90 mm Hg, it is classified as the case 
of ‘high BP’ (hypertension)1. Several factors are respon-
sible for the increase in BP such as kidney diseases, obe-
sity, insulin resistance, high alcohol intake, high salt 
intake, ageing, etc. All these effects result in increased 
BP levels. Genetic factors are also an important cause of 
hypertension. One of the major causes of hypertension is 
the malfunctioning of the renin angiotensin system 
(RAS)2,3. RAS consists of a number of peptides that are 
important in regulation of BP. However, decapeptide  
angiotensin I (Ang I) and the octapeptide angiotensin II 
(Ang II) are particularly important as they directly influ-
ence BP. Ang I is a prohormone, which is converted to 
active hormone Ang II by the cleavage of terminal dipep-
tide (His-Leu)4. This reaction is catalysed by a zinc-
dependent metalloenzyme known as ‘angiotensin con-
verting enzyme’ (ACE). Further, ACE is also responsible 
for the elevation of BP by cleaving the terminal dipeptide 
(Phe–Arg) of vasodilator hormone bradykinin to its  
inactive form (bradykinin 1–7, Figure 1)5,6. 
 Involvement of RAS in elevation of BP was reported 
for the first time by Tigerstedt and Bergman7, who have 
shown that the saline extract of kidney contains some 
vasopressor (material that increases BP) activity. It was 
named ‘renin’ as it was extracted from kidney. In 1940s, 
Braun-Mendez and co-workers8 discovered that renin  
catalyses the formation of the actual pressor agent, the 
‘angiotensinogen’ (also called hypertensinogen). How-
ever, after the separation of two peptide fragments Ang I 
and Ang II, Skeggs et al.4 discovered that it is not the  
angiotensinogen, but the peptides that actually elevate 
BP. They also discovered that the conversion of Ang I to 
Ang II is catalysed by ACE9. However, it took more than 
a decade for Ng and Vane2 and Oparil et al.3 to validate 
that ACE catalyses the conversion of Ang I to Ang II. 
During this period, ACE was first extracted in its pure 
form2,3,10. ACE exists in the peripheral vasculature, proxi-
mal renal tubular cells and the vascular endothelium of 
the lung. Wong et al.11 and Timmermans et al.12 demon-
strated that Ang II acts through two G-protein-coupled 
receptors, AT1 and AT2. The deleterious effects of Ang II 
(e.g. vasoconstriction and cardiac and vascular hypertro-
phy) are mediated by the AT1 receptor, whereas the AT2 
receptor generally mediates opposing effects. 
 In the classical pathway of RAS (Scheme 1), renin, 
which is secreted from the juxtaglomerular apparatus13 of 
the kidneys in response to a variety of stimuli, acts on the 
circulating precursor angiotensinogen14 (23-amino acid 
peptide) to generate a number of small peptides including 
the most important decapeptide, Ang I. This peptide has a 
minor effect on BP. However, cleavage of the C-terminal 
dipeptide (His-Leu) of Ang I generates the octapeptide 
hormone Ang II, which interacts through AT1 and AT2 
receptors. Further, angiotensinase cleaves Ang I or Ang II 
to smaller peptide fractions15,16. Although some of the small 
peptides (e.g. Ang III) has vasopressor activity, Ang II is 
the main vasoconstrictor hormone in the RAS system. 
 In 1926, Petroff17 discovered that extracts from urine 
or pancreas contain a hypotensive substance, which was 
later named as ‘kallikrein’ by Frey et al.18. About a decade 
later, Werle19 discovered that kallikrein releases a  
labile vasoactive peptide from plasma protein and was 
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Figure 1. ACE-catalysed conversion of Ang I to Ang II and bradykinin to bradykinin (1–7). Formation 
of Ang II and depletion of bradykinin concentration result in the elevation of BP. 
 
 
 
 
Scheme 1. RAS is responsible for the production of BP regulating 
hormone Ang II. 
 
 
identified as kallidin (Lys1-bradykinin). The enzyme, 
kinase II degrades bradykinin to its inactive form6. The 
whole system was named as the ‘kallikrein–kinin system’ 
(KKS). Initially, two different research groups worked on 
the RAS and KKS, possibly being unaware that they were 
working on identical research problems. The connection 
was drawn by Erdös et al.20–22 who discovered that kinase 
II and ACE are the same enzyme. This discovery has not 
been easily accepted as the Ang II formation is a highly 
chloride ion-dependent process, whereas bradykinin inac-
tivation is not23,24. However, several years later, it was 
proved that their hypothesis was correct and it was postu-
lated that there are two domains in ACE (N-terminal and 
C-terminal domains)25. The C-terminal domain is highly 
chloride ion-dependent, which catalyses the conversion of 
Ang I to Ang II (Figure 1). Although the N-terminal  
domain active site is similar to that of C-terminal domain, 
it catalyses the inactivation of bradykinin and is not  
anion-dependent. The amino acid sequence of ACE was 
deduced by Soubrier et al.26 from the nucleotide sequence 
of DNA complementary to ACE and found that it has a 
HEXXH + E binding motif for the active site zinc(II) 
binding. The enzyme exists in two isoforms27,28, somatic 
ACE (sACE) and testicular ACE (tACE); which are tran-
scribed from the same gene in tissue-specific manner. 
sACE exists as a single large polypeptide chain of 1277 
amino acid residues, whereas tACE exists as a lower 
mass glycoprotein of 701 amino acid residues. The sACE 
exists as two homologous domains (N- and C-domain) 
with two conserved active sites, whereas tACE is a single 
domain protein. Further, while tACE catalyses the  
conversion of Ang I to Ang II, sACE catalyses the con-
version of bradykinin to bradykinin (1–7). 
ACE inhibitors 
In the 1960s, scientists studying RAS and KKS realized 
that inhibition of ACE is important for the treatment of 
high BP. A breakthrough was achieved in 1965 when  
Ferreira29 for the first time described that the snake 
venom of Bothrops jararaca exhibits some bradykinin-
potentiating activity. In 1968, Bakhle30 discovered that 
the same extract inhibits the formation of Ang II from 
Ang I in vitro. Two years later, Ng and Vane31 demon-
strated the ACE inhibitory effect of the snake venom in 
vivo. The venom extract was first purified at the Squibb 
Institute for Medical Research and the most potent ACE 
inhibitor was identified as a nonapeptide (teprotide)32,33. 
This nonapeptide was administered intravenously as an 
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Scheme 2. Synthesis of captopril as reported by Cushman and Ondetti35. 
 
 
antihypertensive drug. However, an oral administration of 
this peptide was not possible. This led to a search for an 
oral antihypertensive drug correlated to the structure and 
activity of snake venom. In 1976, Cushman and Ondetti 
synthesized Captopril (1)34,35, the first orally active ACE 
inhibitor. Captopril is a competitive inhibitor of ACE and 
contains a proline residue for the binding at the enzyme 
active site and a thiol moiety for coordination to zinc(II). 
It was approved by the Food and Drug Administration, 
USA for treatment of human hypertension in 1981. 
Cushman and Ondetti synthesized captopril by following 
the procedure given in Scheme 2. Diastereomeric resolu-
tion of the optical centre was one of the major steps in the 
synthesis as it was observed that the compound having 
(S, S) configuration exhibits ~3 orders of magnitude  
better ACE inhibition behaviour than the (R, S) diastereo-
mer35. It was achieved by treating the diastereomer with 
dicyclohexyl amine in the presence of chloroform and 
acetonitrile. It should be noted that the (S, S) diastereo-
mer precipitates first owing to the difference in solubility, 
leaving the other conformer in solution. 
 Since the discovery of captopril, several related com-
pounds such as zofenopril (2), enalapril (3), fosinopril 
(4), lisinopril (5), ramipril (6), tandolapril (7), perindopril 
(8), spirapril (9), rentiapril (10), alacepril (11), benzapril 
(12), quinapril (13), moexipril (14), cilazapril (15) were 
developed as ACE inhibitors on the basis of structure-
based drug design and are successfully used as antihyper-
tensive drugs36–38. Most of these inhibitors contain a 
proline (or derivative) residue as shown in Figure 2. 
 ACE inhibition activity can be measured either in vitro 
or in vivo. In vitro studies demonstrate the conversion of 
Ang I to Ang II with the help of various separation and 
spectroscopic techniques. Another in vitro method for 
analysing ACE activity involves the conversion of Hip 
(hippuryl)-His-Leu to hippuric acid and His-Leu peptides 
as shown in Scheme 3. Hip-His-Leu is a tripeptide analogue 
of Ang I and, can be synthesized in large quantities. Fur-
ther, the Km value observed for the ACE-mediated cataly-
sis for this tripeptide is ~20 times greater than that of  
Ang I39. It should be noted that the ACE activity is very
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Some of the ACE inhibitors used as antihypertensive drugs. 
 
 
specific to temperature and pH even under in vitro condi-
tions. This enzyme shows optimal activity at 37°C at a 
pH of 8.3. Radiochemical assays are used as one of the 
main tools for in vivo studies of ACE activity40. 
Binding of ACE inhibitors at the active site 
ACE inhibitors can be classified on the basis of their  
interaction with the active site zinc(II) centre. Inhibitors 
such as captopril, zofenopril, rentiapril, alacepril bind to 
the metal centre through the thiol moiety, leading to the 
formation of zinc(II)-thiolates. Compounds such as enalar-
pril, lisinopril, ramipril, spirapril, etc. interact through 
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Scheme 3. Hydrolysis of Hip-His-Leu tripeptides by ACE. 
 
 
 
 
Figure 3. Secondary structure of tACE determined by X-ray crystal-
lographic studies41. 
 
 
 
Figure 4. Binding of captopril and its analogues to the ACE active 
site. 
 
 
the carboxylate moiety and fosinopril interacts through the 
phosphate group. In addition to the coordination with  
the active site metal centre, these inhibitors interact with the 
binding pockets present at the active site of ACE. There-
fore, the side chains and stereochemistry of inhibitors 
play a crucial role. The structural detail of inhibitor 
bound lisinopril was first reported by Acharya and  
co-workers41. Since then, a number of ACE-bound inhibitor 
crystals have been reported42–46. From the crystal struc-
ture of the enzyme (Figure 3), it was found that the en-
zyme consists of 27 helices (96% of the total amino acid 
residues) and six relatively short β-strands. The overall 
shape is ellipsoid (approx. dimension, 72 × 52 × 48 Å) 
with a central groove that extends for about 30 Å into the 
active site and divides the enzyme into two sub-domains. 
The cavity is covered by four helices and a β-strand. 
Three of these helices contain charged amino acid resi-
dues and restrict the access of larger polypeptides to the 
active site cleft. Two chloride ions are bound to the interior 
of the enzyme with a highly ordered active site contain-
ing zinc(II) ion. The active site containing zinc(II) is 
bound to HEXXH + E motif (His 383, His 387 and Glu 
411) with a water coordination at the fourth position. 
 There are four binding subsites (S1, S2, S1′ and S2′) 
present at the active site of the enzyme. Captopril binds 
competitively to the Zn(II) centre through the thiolate co-
ordination (Zn–S distance, 2.32 Å). The central carbonyl 
group between the thiol moiety and the terminal praline 
residue is positioned by two strong hydrogen bonds from 
the two histidines (His 513, 2.69 Å; His 353, 2.54 Å). The 
captopril–ACE complex is further stabilized by another 
interaction through one of the oxygen atoms of the 
proline carboxylate with Tyr 520 (2.66 Å), Gln 281 (3.1 Å), 
and Lys 511 (2.73 Å)44. tACE and N- and C-domains of 
sACE have different amino acid residues at these sub-
sites44–46. However, the nature of the amino acid side 
chains in these subsites are similar in all these active sites. 
The interaction of inhibitors at these subsites depends on 
the nature of the side chains. For example, captopril (1) 
interacts with subsite S1′ and S2′ through central car-
bonyl and the proline residue respectively44. Similar in-
teractions were observed in the zofenopril (2)–ACE 
complex. However, in the case of enalapril (3) and fosi-
nopril (4), there are evidences of additional interactions 
at subsites S1 and S2 through the aromatic residue44,45. 
For example, in the case of enalapril, the aromatic residue 
stabilizes the enzyme–inhibitor complex by interacting 
with the hydrophobic pocket generated by Phe 512 and 
Val 518 residues. Figure 4 provides a pictorial represen-
tation of the ACE–inhibitor interactions. 
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ACE inhibitors in the treatment of hypertension 
In addition to ACE inhibitors, compounds such as diuretics, 
beta-blockers, Ang II receptor antagonists and calcium 
channel blockers are used in the treatment of hyperten-
sion. Among these compounds, ACE inhibitors are con-
sidered as the safest class of antihypertensive drugs47. 
However, a combination of such drugs is considered to be 
more effective in the treatment of hypertension47. For  
example, combination therapy of two diuretics, diuretic-
beta blockers, ACE inhibitor-beta blockers, Ang II recep-
tor antagonists–diuretics, etc. are some of the commonly 
used drugs in combination therapy. All these different 
drugs have their own advantages and limitations depend-
ing on the nature and cause of hypertension. Recently, it 
was demonstrated that hypertension is associated with 
another disease state called oxidative stress48–52. ‘Oxida-
tive stress’ is a condition caused mainly by an imbalance 
between the production of reactive oxygen species (ROS) 
and a biological system’s ability to readily detoxify the 
reactive intermediates or easily repair the resulting dam-
ages53,54. Small amounts of highly reactive oxidants such 
as superoxide radical anion (O•2–) hydroxyl radical (•OH) 
and hydrogen peroxide (H2O2), etc. are essential for an 
organism to perform various metabolic cycles. The cellular 
concentration of these oxidants is maintained by antioxi-
dants, which undergo oxidation to prevent the oxidation 
of other molecules. Mammalian enzymes such as gluta-
thione peroxidase (GPx), superoxide dismutase (SOD), 
catalase and cofactors such as glutathione (GSH) are 
mainly involved in the natural antioxidant defence 
mechanism. 
Hypertension and oxidative stress 
ROS and reactive nitrogen species (RNS) play a crucial 
role in the pathogenesis of various cardiovascular disease 
states48 such as inflammation, ischemia–reperfusion, 
coronary artery diseases, atherosclerosis, diabetes, hyper-
tension, etc. ROS such as superoxide radical anion (O•2–) 
react with the nitric oxide radical (•NO), thereby decreas-
ing the cellular •NO concentration. The maintenance of 
the concentration of nitric oxide is important as it is the 
endothelial-derived relaxing factor49 and a neurotransmit-
ter. Further, the reaction of these two reactive species 
generates peroxynitrite (PN, ONOO–)50, which is consid-
ered as both ROS and RNS. It nitrates several tyrosine 
residues in proteins leading to cardiovascular remodel-
ling. PN also oxidizes arachidonic acid51,52, a precursor 
for production of vasodilating hormone prostaglandin. 
 Ang II can directly modulate vascular cell growth, dif-
ferentiation and gene expression pathways. Further, Ang 
II-mediated hypertension is also known to be closely  
associated with oxidative stress55,56. It is well established 
that there is an overexpression of NADPH oxidase genes 
owing to overproduction of Ang II, which induces 
NADPH oxidase enzyme to release excess of O•2– (refs 
57–59). As a result, there is an overproduction of PN, 
leading to protein nitration. Ang II also contains a tyro-
sine residue and is susceptible to PN-mediated nitration. 
Nitration of Ang II leads to a complete loss of its vaso-
constricting effect in vivo60. However, nitration of Ang II 
leads to endothelial dysfunction and is associated with 
other cardiovascular complications48. Treatment of hyper-
tensive animals/humans with a combination therapy of 
ACE inhibitors and vitamin C or E reduces their cardio-
vascular risk factor. Owing to the antioxidant effect of  
vitamin C and E, which scavenge free radicals in lipid 
membranes and cytosol61. Further, there are also eviden-
ces that ACE inhibitors such as captopril exhibit some 
beneficial effects in the treatment of myocardial ische-
mia-reperfusion62,63. This led to studies on the beneficial 
effects of sulphur-containing ACE inhibitors. A compari-
son of the antihypertensive action of ACE inhibitory 
drugs captopril (1), zofenopril (2) and fosinopril (4) illu-
strates that zofenopril is a better antihypertensive drug 
than captopril followed by fosinopril. The better anti-
hypertensive action of zofenopril results from its ability 
to scavenge ROS64,65. Similarly, zofenopril has been 
shown to be a better antihypertensive drug than enalapril 
(3) owing to its antioxidant activities, although the latter 
is a better ACE inhibitor. Zofenopril and captopril having 
a sulphur moiety can readily be oxidized to sulphoxides, 
and therefore, can provide better protection against oxida-
tive damage. 
 Recently, we have reported the synthesis and inhibition 
studies of ACE activity and PN-mediated nitration of 
peptides by a series of compounds having selenium moiety 
(compounds 16–19, Figure 5)66,67. It is observed that the 
selenium analogue of captopril (16, IC50: 36.4 ± 1.5 nM) 
shows ACE inhibition activity similar to that of  
captopril66 (IC50: 18.1 ± 1.0 nM). However, selenium 
compounds are better scavengers of PN than their sulphur 
 
 
 
Figure 5. Selenium-containing compounds that exhibit both ACE inhibitory and antioxidant activities. 
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Table 1. IC50 values for inhibition of PN-mediated nitration of Ang II  
  by compounds 1, 16–19 (refs 66 and 67) 
Compound  IC50 (μM)  Compound  IC50 (μM) 
 
1  25.6 ± 0.9  16  2.2 ± 0.1 
17   4.5 ± 0.2  18  6.0 ± 0.5 
19   7.0 ± 0.1 
 
 
analogues. It should be noted that PN can nitrate the Tyr 
residues in proteins and peptides. As Ang II contains a 
Tyr residue, effect of these ACE inhibitors on the inhibi-
tion of PN-mediated nitration of Ang II has been studied. 
The IC50 values obtained for the inhibition of PN-
mediated nitration of Ang II by these compounds are 
listed in Table 1. The effect of various substituents on 
Se–captopril was similar to that of captopril. For example, 
captopril and Se–captopril are competitive inhibitors of 
ACE. Similar to captopril, the S, S isomer of Se–captopril 
is ~200 times more potent as inhibitor of ACE than the 
R, S isomer. These observations indicate that the binding 
of Se–captopril at the active site of ACE may be similar 
to that of captopril. Although selenium was considered to 
be a poison for a long time, it is now considered as an  
essential trace element in mammals. Selenium is mainly 
associated with the antioxidant enzymes such as GPx, 
where selenocysteine is the active site residue. Therefore, 
detailed pharmacological investigation for these com-
pounds is essential for the development of a new class of 
combination therapy for hypertensive patients. 
 
 
1. Carretero, O. A. and Oparil, S., Essential hypertension: Part I: 
Definition and etiology. Circulation, 2000, 101, 329–325. 
2. Ng, K. K. and Vane, J. R., Conversion of angiotensin I to angio-
tensin II. Nature, 1967, 216, 762–766. 
3. Oparil, S., Sanders, C. A. and Haber, E., Role of renin in acute 
postural homeostasis. Circulation, 1970, 41, 89–95. 
4. Skeggs, L. T., Marsh, W. H., Kahn, J. R. and Shumway, N. P., The 
existence of two forms of hypertensin. J. Exp. Med., 1954, 99, 
275–283. 
5. Ng, K. K. and Vane, J. R., Fate of angiotensin I in the circulation. 
Nature, 1968, 218, 144–150. 
6. Vane, J. R., The release and fate of vaso-active hormones in the 
circulation. Br. J. Pharmacol., 1969, 35, 209–242. 
7. Tigerstedt, R. and Bergman, P. G., Niere und kreislauf. Skand. 
Arch. Physiol., 1898, 8, 223–227. 
8. Braun-Mendez, E., Fasciolo, J. C., Leloir, L. F. and Munoz, J. M., 
The substance causing renal hypertension. J. Physiol., 1940, 98, 
283–298. 
9. Skeggs, L. T., Marsh, W. H., Kahn, J. R. and Shumway, N. P.,  
The purification of hypertensin I. J. Exp. Med., 1954, 100, 363–
370. 
10. Oparil, S., Tregear, G. W., Koerner, T., Barnes, B. A. and Haber, 
E., Mechanism of pulmonary conversion of anglotensin I to angio-
tensin II in the dog. Circ. Res., 1971, 29, 682–690. 
11. Wong, P. C., Hart, S. D., Zaspel, A. M., Chiu, A. T., Ardecky, J., 
Smith, R. D. and Timmermans, P. B. M. W. M., Functional studies 
of nonpeptide angiotensin II receptor subtype-specific ligands: 
DuP 753 (AII-1) and PD123177 (AII-2). J. Pharmacol. Exp. 
Ther., 1990, 255, 584–592. 
12. Timmermans, P. B. M. W. M., Wong, P. C., Chiu, A. T. and 
Herblin, W. F., Nonpeptide angiotensin II receptor antagonists. 
Trends Pharmacol. Sci., 1991, 12, 55–61. 
13. Kon, Y., Hashimoto, Y., Kitagawa, H. and Kudo, N., Morphology 
and quantification of juxtaglomerular cells of the chicken kidney. 
Jap. J. Vet. Sci., 1984, 46, 189–196. 
14. Kon, Y., Local renin-angiotensin system: especially in coagulating 
glands of mice. Arch. Histol. Cytol., 1996, 59, 399–420. 
15. Rosivall, L., Intrarenal renin-angiotensin system. Mol. Cell. Endo-
crinol., 2009, 302, 185–192. 
16. Ferrario, C. M., Chappell, M. C., Dean, R. H. and Iyer, S. N., 
Novel angiotensin peptides regulate blood pressure, endothelial 
function and natriuresis. J. Am. Soc. Nephrol., 1998, 9, 1716–
1722. 
17. Webster, M. E., Kallikreins in glandular tissues. In Bradykinin, 
Kallidin and Kallikrein. Handbook of Experimental Pharmacology 
(ed. Erdös, E. G.), Springer Verlag, Berlin, 1970, vol. XXV, pp. 
131–155. 
18. Frey, E. K., Kraut, H. and Werle, E., Kallikrein: Padutin, Ferdi-
nand enke Verlag, Stuttgart, 1950. 
19. Werle, E., Discovery of the most important kallikreins and kallik-
rein inhibitors. In Bradykinin, Kallidin and Kallikrein. Handbook 
of Experimental Pharmacology (ed. Erdös, E. G.), Springer Ver-
lag, Berlin, 1970, vol. XXV, pp. 1–6. 
20. Erdös, E. G. and Yang, H. Y. T., An enzyme in microsomal fraction 
of kidney that inactivates bradykinin. Life Sci., 1967, 6, 569–574. 
21. Yang, H. Y. T. and Erdös, E. G., Second kininase in human blood 
plasma. Nature, 1967, 215, 1402–1403. 
22. Yang, H. Y. T., Erdös, E. G. and Levin, Y., A dipeptidyl carboxy-
peptidase that converts angiotensin I and inactivates bradykinin. 
Biochim. Biophys. Acta, 1970, 214, 374–376. 
23. Igic, R., Erdös, E. G., Yeh, H. S. J., Sorrels, K. and Nakajima, T., 
The angiotensin I converting enzyme of the lung. Circ. Res., 1972, 
31, II-51–61. 
24. Skeggs, L. T., Dorer, F. E., Kahn, J. R., Lentz, K. E. and Levin, 
M., Experimental renal hypertension: the discovery of the renin–
angiotensin system. In Biochemical Regulation of Blood (ed. Sof-
fer, R.), John Wiley, Hoboken, 1981, pp. 3–38. 
25. Jaspard, E., Wei, L. and Alhenc-Gelas, F., Differences in the 
properties and enzymatic specificities of the two active sites of 
angiotensin I-converting enzyme (kininase II). Studies with bra-
dykinin and other natural peptides. J. Biol. Chem., 1993, 268, 
9496–9503. 
26. Soubrier, F., Alhenc-Gelas, F., Hubert, C., Allegrini, J., John, M., 
Tregear, G. and Corvol, P., Two putative active centers in human 
angiotensin I-converting enzyme revealed by molecular cloning. 
Proc. Natl. Acad. Sci. USA, 1988, 85, 9386–9390. 
27. Ehlers, M. R. W., Fox, E. A., Strydom, D. J. and Riordan, J. F., 
Molecular cloning of human testicular angiotensin-converting  
enzyme: The testis isozyme is identical to the C-terminal half of 
endothelial angiotensin-converting enzyme. Proc. Natl. Acad. Sci. 
USA, 1989, 86, 7741–7745. 
28. Ehlers, M. R. W. and Riordan, J. F., Angiotensin-converting enzyme: 
Zinc- and inhibitor-binding stoichiometries of the somatic and  
testis isozymes. Biochemistry, 1991, 30, 7118–7126. 
29. Ferreira, S. H., Bradykinin-potentiating factor. In Hypotensive 
Peptides. Proceedings of the International Symposium (eds Erdös, 
E. G., Back, N. and Sicuteri, F.), Firenze, Italy, Springer-Verlag, 
New York, 1965, pp. 356–367. 
30. Bakhle, Y. S., Conversion of angiotensin I to angiotensin II by 
cell-free extracts of dog lung. Nature, 1968, 220, 919–921. 
31. Ng, K. K. and Vane, J. R., Some properties of angiotensin  
converting enzyme in the lung in vivo. Nature, 1970, 225, 1142–
1144. 
32. Ferreira, S. H., Bartelt, D. C. and Greene, L. J., Isolation of  
bradykinin-potentiating peptides from Bothrops jararaca venom. 
Biochemistry, 1970, 9, 2583–2593. 
CHEMISTRY – STRUCTURE, SYNTHESIS AND DYNAMICS  
 
CURRENT SCIENCE, VOL. 101, NO. 7, 10 OCTOBER 2011 887
33. Ondetti, M. A., Williams, N. J., Sabo, E. F., Pluščec, J., Weaver, 
E. R. and Kocy, O., Angiotensin-converting enzyme inhibitors 
from the venom of Bothrops jararaca. Isolation, elucidation of 
structure, and synthesis. Biochemistry, 1971, 10, 4033–4039. 
34. Ondetti, M. A., Rubin, B. and Cushman, D. W., Design of specific 
inhibitors of angiotensin-converting enzyme: new class of orally 
active antihypertensive agents. Science, 1977, 196, 441–444. 
35. Cushman, D. W., Cheung, H. S., Sabo, E. F. and Ondetti, M. A., 
Design of potent competitive inhibitors of angiotensin-converting 
enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids. 
Biochemistry, 1977, 16, 5484–5491. 
36. Cushman, D. W. and Ondetti, M. A. Design of angiotensin con-
verting enzyme inhibitors. Nat. Med., 1999, 5, 1110–1112 A. 
37. Patchett, A. A. et al., A new class of angiotensin-converting  
enzyme inhibitors. Nature, 1980, 288, 280–283. 
38. Petrillo, E. W. et al., In Peptides: Structure and Function. Proceed-
ings of the Eighth American Peptide Symposium (eds Hurby, V. J. 
and Rich, D. H.), Pierce Chemical Co, Rockford, 1983, p. 541. 
39. Meng, Q. C. and Oparil, S., Purification and assay methods for 
angiotensin-converting enzyme. J. Chromatogr. A, 1996, 743, 
105–122. 
40. Meng, Q. C., Balcells, E., Dell’italia, L., Durand, J. and Oparil, S., 
Sensitive method for quantitaion of angiotensin-converting en-
zyme (ACE) activity in tissue. Biochem. Pharmacol., 1995, 50, 
1445–1450. 
41. Natesh, R., Schwager, S. L. U., Sturrock, E. D. and Acharya, K. 
R., Crystal structure of the human angiotensin-converting  
enzyme–lisinopril complex. Nature, 2003, 421, 551–554. 
42. Sturrock, E. D., Natesh, R., Rooyen, J. M. V. and Acharya, K. R., 
Structure of angiotensin I-converting enzyme. Cell. Mol. Life Sci., 
2004, 61, 2677–2686. 
43. Kim, H. M., Shin, D. R., Yoo, O. J., Lee, H. and Lee, J. O., Crys-
tal structure of drosophila angiotensin I converting enzyme bound 
to captopril and lisinopril. FEBS Lett., 2003, 538, 65–70. 
44. Natesh, R., Schwager, S. L. U., Evans, H. R., Sturrock, E. D. and 
Acharya, K. R., Structural details on the binding of antihyperten-
sive drugs captopril and enalaprilat to human testicular angio-
tensin I-converting enzyme. Biochemistry, 2004, 43, 8718–8724. 
45. Corradi, H. R., Chitapi, I., Sewell, B. T., Georgiadis, D., Dive, V., 
Sturrock, E. D. and Acharya, K. R., The structure of testis angio-
tensin-converting enzyme in complex with the C domain-specific 
inhibitor RXPA380. Biochemistry, 2007, 46, 5473–5478. 
46. Akif, M., Georgiadis, D., Mahajan, A., Dive, V., Sturrock, E. D., 
Isaac, R. E. and Acharya, K. R., High-resolution crystal structures 
of Drosophila melanogaster angiotensin-converting enzyme in 
complex with novel inhibitors and antihypertensive drugs. J. Mol. 
Biol., 2010, 400, 502–517. 
47. Skolnik, N. S., Beck, J. D. and Clark, M., Combination antihyper-
tensive drugs: Recommendations for use. Am. Fam. Physician, 
2000, 61, 3049–3056. 
48. Turko, V. and Murad, F., Protein nitration in cardiovascular  
diseases. Pharmacol. Rev., 2002, 54, 619–634. 
49. Pecháňová, O. and Šimko, F., The role of nitric oxide in the mainte-
nance of vasoactive balance. Phys. Res., 2007, 56(suppl. 2), S7–S16. 
50. Radi, R., Nitric oxide, oxidants, and protein tyrosine nitration. 
Proc. Natl. Acad. Sci. USA, 2004, 101, 4003–4008. 
51. Romero, J. C. and Reckelhoff, J. F., Role of angiotensin and oxi-
dative stress in essential hypertension. Hypertension, 1999, 34, 
943–949. 
52. Irani, K., Oxidant signaling in vascular cell growth, death, and 
survival: A review of the roles of reactive oxygen species in 
smooth muscle and endothelial cell mitogenic and apoptotic  
signaling. Circ. Res., 2000, 87, 179–183. 
53. Sies, H. (ed.), Oxidative stress: Introductory remarks. In Oxidative 
Stress, Academic Press, London, 1985, p. 1. 
54. Sies, H., Biochemistry of oxidative stress. Angew. Chem. Int. Ed., 
1986, 25, 1058–1071. 
55. Alexander, R. W., Hypertension and the pathogenesis of athero-
sclerosis. Hypertension, 1995, 25, 155–161. 
56. Kunsch, C. and Medford, R. M., Oxidative stress as a regulator of 
gene expression in the vasculature. Circ. Res., 1999, 85, 753–766. 
57. Griendling, K. K., Minieri, C. A., Ollerenshaw, J. D. and Alexan-
der, R. W., Angiotensin II stimulates NADH and NADPH oxidase 
activity in cultured vascular smooth muscle cells. Circ. Res., 1994, 
74, 1141–1148. 
58. Rajagopalan, S., Kurz, S., Münzel, T., Tarpey, M., Freeman, B. A., 
Griendling, K. K. and Harrison, D. G., Angiotensin II-mediated 
hypertension in the rat increases vascular superoxide production 
via membrane NADH/NADPH oxidase activation contribution to 
alterations of vasomotor tone. J. Clin. Invest., 1996, 97, 1916–
1923. 
59. Mihm, M. J., Wattanapitayakul, S. K., Piao, S.-F., Hoyt, D. G. and 
Bauer, J. A., Effects of angiotensin II on vascular endothelial 
cells: formation of receptor-mediated reactive nitrogen species. 
Biochem. Pharmacol., 2003, 65, 1189–1197. 
60. Ducrocq, C. et al., Chemical modifications of the vasoconstrictor 
peptide angiotensin II by nitrogen oxides (NO, HNO2, HOONO): 
Evaluation by mass spectrometry. Eur. J. Biochem., 1998, 253, 
146–153. 
61. Tian, N., Thrasher, K. D., Gundy, P. D., Hughson, M. D. and 
Manning Jr, R. D., Antioxidant treatment prevents renal damage 
and dysfunction and reduces arterial pressure in salt-sensitive  
hypertension. Hypertension, 2005, 45, 934–939. 
62. Mak, T., Freedman, A. M., Dickens, B. F. and Weglicki, W., Pro-
tective effects of sulfhydryl-containing angiotensin converting  
enzyme inhibitors against free radical injury in endothelial cells. 
Biochem. Pharmacol., 1990, 40, 2169–2175. 
63. Liu, X., Engelman, R. M., Rousou, J. A., Cordis, G. A. and Das, 
D. K., Attenuation of myocardial reperfusion injury by sulfhydryl-
containing angiotensin converting enzyme inhibitors. Cardiovasc. 
Drugs Ther., 1992, 6, 437–443. 
64. Subissi, A., Evangelista, S. and Giachetti, A., Interactions between 
NO and reactive oxygen species: Pathophysiological importance 
in atherosclerosis, hypertension, diabetes and heart failure. Car-
diovasc. Drug Rev., 1999, 17, 115–133. 
65. Evangelista, S. and Manzini, S., Antioxidant and cardioprotective 
properties of the sulphydryl angiotensin-converting enzyme  
inhibitor Zofenopril. J. Int. Med. Res., 2005, 33, 42–54. 
66. Bhuyan, B. J. and Mugesh, G., Angiotensin converting enzyme 
inhibitors with antioxidant activity. Org. Biomol. Chem., 2011, 9, 
1356–1365. 
67. Bhuyan, B. J. and Mugesh, G., Effect of peptide-based captopril 
analogues on angiotensin converting enzyme activity and per-
oxynitrite-mediated tyrosine nitration. Org. Biomol. Chem., 2011, 
9, 5185–5192. 
 
 
ACKNOWLEDGEMENTS. G.M. thanks the Department of Science 
and Technology, New Delhi for the Ramanna and Swarnajayanti  
fellowships. B.J.B. thanks the Council of Scientific and Industrial  
Research, New Delhi and Indian Institute of Science, Bangalore for a 
research fellowships. 
 
